TAIHUSNOW CO.,LTD.
838262
Guangdong Brandmax Marketing
300805
Guangdong Transtek Medical Electronics
300562
Suzhou Kingswood Education Technology
300192
Broadex Technologies
300548
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 15.18%534.73M | 11.25%348.61M | 4.69%119.45M | 29.36%697.2M | 65.20%464.25M | 69.70%313.36M | 219.31%114.1M | 35.87%538.96M | 58.63%281.02M | 184.65M |
Operating revenue | 15.18%534.73M | 11.25%348.61M | 4.69%119.45M | 29.36%697.2M | 65.20%464.25M | 69.70%313.36M | 219.31%114.1M | 35.87%538.96M | 58.63%281.02M | --184.65M |
Total operating cost | 18.47%492.46M | 15.39%319.6M | 0.15%106.5M | 33.08%602.39M | 66.39%415.67M | 72.54%276.96M | 156.57%106.34M | 30.71%452.65M | 249.81M | 160.52M |
Operating cost | 18.68%377.77M | 15.81%249.24M | -6.54%74.31M | 33.26%468.99M | 70.72%318.32M | 77.22%215.21M | 239.39%79.51M | 30.01%351.92M | --186.46M | --121.43M |
Operating tax surcharges | 5.85%3.04M | -13.29%1.81M | -21.88%479.63K | -9.78%3.91M | 13.27%2.87M | 30.00%2.09M | -64.89%613.96K | 66.45%4.33M | --2.53M | --1.61M |
Operating expense | -6.74%20.58M | 18.72%15.64M | 34.60%6.94M | 60.03%30.15M | 86.05%22.07M | 66.22%13.17M | 143.38%5.15M | 20.71%18.84M | --11.86M | --7.93M |
Administration expense | 31.92%28.72M | 32.92%17.98M | 28.05%8.67M | 1.31%29.62M | 7.57%21.77M | 9.67%13.53M | 18.14%6.77M | 24.75%29.24M | --20.24M | --12.34M |
Financial expense | 90.72%1.8M | -41.62%1.02M | -105.65%-42.43K | 1.38%291.89K | 418.94%941.95K | 397.35%1.75M | 248.74%750.99K | -89.35%287.93K | ---295.34K | ---589.66K |
-Interest expense (Financial expense) | -52.79%1.33M | -47.42%1.08M | -57.70%395.36K | 131.20%2.84M | 548.27%2.83M | 1,871.75%2.06M | 133.18%934.75K | -65.79%1.23M | --435.81K | ---116.19K |
-Interest Income (Financial expense) | 6.31%-1.98M | -302.08%-1.67M | -90.01%-453.18K | -228.02%-2.85M | -240.46%-2.11M | 5.44%-414.61K | -8.48%-238.51K | 23.96%-868.43K | ---620.79K | ---438.47K |
Research and development | 21.83%60.56M | 8.63%33.9M | 19.23%16.14M | 44.56%69.43M | 71.31%49.71M | 75.21%31.21M | 65.02%13.54M | 53.55%48.03M | --29.01M | --17.81M |
Credit Impairment Loss | -151.93%-27.15M | -54.85%-11.4M | -98.43%-5.96M | -29.52%-19.8M | -172.86%-10.78M | -85.11%-7.36M | 21.32%-3M | -76.96%-15.28M | ---3.95M | ---3.98M |
Asset Impairment Loss | 25.84%-4.1M | 24.44%-3.18M | 41.21%-967.51K | -38.30%-6.6M | -37.70%-5.53M | -76.95%-4.2M | -143.90%-1.65M | 6.33%-4.77M | ---4.02M | ---2.38M |
Other net revenue | ||||||||||
Fair value change income | 282.44%10.03M | 676.74%6.8M | 228.34%4.67M | 129.60%6.14M | 29.36%2.62M | -26.09%875.18K | 56.08%1.42M | 1,408.47%2.67M | --2.03M | --1.18M |
Invest income | 146.89%9.5M | 121.59%6.89M | 368.74%2.29M | 75.82%6.68M | 34.34%3.85M | 49.72%3.11M | -20.36%489.11K | 581.18%3.8M | --2.86M | --2.08M |
Asset deal income | ---- | ---- | ---- | -99.21%26.62K | -99.45%18.49K | -99.39%20.75K | ---11.86K | 478.11%3.38M | --3.38M | --3.38M |
Other revenue | 162.46%26.81M | 64.41%10.92M | 30.28%1.56M | -9.89%20.81M | 9.08%10.21M | -20.14%6.64M | -67.23%1.2M | 186.20%23.09M | --9.36M | --8.32M |
Operating profit | 17.11%57.36M | 10.04%39.04M | 134.45%14.54M | 2.90%102.08M | 19.81%48.98M | 8.39%35.48M | 223.24%6.2M | 122.76%99.2M | 40.88M | 32.73M |
Add:Non operating Income | 89.19%422.32K | -91.07%19.41K | -96.20%8.11K | 149,648.42%1.5M | --223.23K | --217.49K | --213.49K | -96.24%1K | ---- | ---- |
Less:Non operating expense | 555.55%547.88K | 463.30%78.39K | -95.91%344.01 | 204.18%354.78K | 9.59%83.58K | -31.41%13.92K | 4,952.65%8.42K | -73.24%116.64K | --76.26K | --20.29K |
Total profit | 16.53%57.23M | 9.25%38.98M | 127.07%14.55M | 4.18%103.22M | 20.38%49.12M | 9.08%35.68M | 227.31%6.41M | 124.56%99.08M | 40.8M | 32.71M |
Less:Income tax cost | -215.46%-3.64M | -35.73%-535.82K | 51.67%-1.1M | -59.49%2.1M | -8,141.09%-1.15M | -123.49%-394.78K | -1.58%-2.27M | 168.99%5.19M | --14.34K | --1.68M |
Net profit | 21.09%60.87M | 9.54%39.52M | 80.33%15.65M | 7.69%101.12M | 23.25%50.27M | 16.26%36.08M | 409.89%8.68M | 122.53%93.89M | 287.71%40.79M | 31.03M |
Net profit from continuing operation | 21.09%60.87M | 9.54%39.52M | 80.33%15.65M | 7.69%101.12M | 23.25%50.27M | 16.26%36.08M | 409.89%8.68M | 122.53%93.89M | --40.79M | --31.03M |
Less:Minority Profit | --5.29M | ---861.79K | ---194.92K | ---1.83K | ---- | ---- | ---- | ---- | ---- | ---- |
Net profit of parent company owners | 10.56%55.58M | 11.93%40.38M | 82.58%15.84M | 7.70%101.12M | 23.25%50.27M | 16.26%36.08M | 409.89%8.68M | 122.53%93.89M | 287.71%40.79M | --31.03M |
Earning per share | ||||||||||
Basic earning per share | -10.61%0.59 | -15.69%0.43 | 41.67%0.17 | -6.06%1.24 | 15.79%0.66 | 18.60%0.51 | 400.00%0.12 | 94.12%1.32 | --0.57 | --0.43 |
Diluted earning per share | -10.61%0.59 | -15.69%0.43 | 41.67%0.17 | -6.06%1.24 | 15.79%0.66 | 18.60%0.51 | 400.00%0.12 | 94.12%1.32 | --0.57 | --0.43 |
Other composite income | ||||||||||
Total composite income | 21.09%60.87M | 9.54%39.52M | 80.33%15.65M | 7.69%101.12M | 23.25%50.27M | 16.26%36.08M | 409.89%8.68M | 122.53%93.89M | 40.79M | 31.03M |
Total composite income of parent company owners | 10.56%55.58M | 11.93%40.38M | 82.58%15.84M | 7.70%101.12M | 23.25%50.27M | 16.26%36.08M | 409.89%8.68M | 122.53%93.89M | --40.79M | --31.03M |
Total composite income of minority owners | --5.29M | ---861.79K | ---194.92K | ---1.83K | ---- | ---- | ---- | ---- | ---- | ---- |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.